Drug Detail

Drug Name Atezolizumab
Trade Name Tecentriq
Synonyms RG7446|MPDL3280A
Drug Descriptions

Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).

DrugClasses Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 49

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Atezolizumab + Cisplatin + Gemcitabine
Atezolizumab + Enfortumab vedotin
Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin
Atezolizumab + Fulvestrant
Atezolizumab + Obinutuzumab + RO6958688 RO6958688 is a bispecific antibody that binds to CD3 and human anti-carcinoembryonic antigen (CEA) simultaneously, which may lead to cytotoxic immune response against CEA-positive tumor cells (NCI Drug Dictionary).
Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab
Atezolizumab + Bendamustine + Obinutuzumab
Atezolizumab + Rogaratinib
Atezolizumab + Veliparib
Atezolizumab + Pertuzumab + Trastuzumab
Atezolizumab + Epacadostat
Atezolizumab + MTIG7192A
Atezolizumab + Emactuzumab
Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed
Atezolizumab + Carboplatin + Pemetrexed
Atezolizumab + Niraparib
Atezolizumab + BCG solution
Atezolizumab + Varlilumab
Atezolizumab + Ipatasertib
Atezolizumab + Linagliptin
Atezolizumab + KTE-C19
Atezolizumab + Docetaxel
Atezolizumab + Cobimetinib
Atezolizumab + KY1044 KY1044 is a monoclonal antibody that targets ICOS, which has potential anti-tumor activity (Cancer Res 2018;78(13 Suppl):Abstract nr 2792).
Atezolizumab + Bevacizumab
Atezolizumab + Rituximab
Atezolizumab + PRS-343
Atezolizumab + RO6958688
Atezolizumab + Bevacizumab + Cobimetinib
Atezolizumab + Enzalutamide
Atezolizumab + RO7198457
Atezolizumab + Ipilimumab
Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed
Atezolizumab + Talimogene laherparepvec
Atezolizumab + Carboplatin + Gemcitabine
Atezolizumab + Ramucirumab Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (NCI Drug Dictionary). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and colorectal cancer (FDA.gov).
Atezolizumab + Hu5F9-G4 Tecentriq (atezolizumab) is a monoclonal antibody that binds to PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, and in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1 (FDA.gov).
Atezolizumab + Bevacizumab + Exemestane
Atezolizumab + Cobimetinib + Niraparib
Atezolizumab + Ipatasertib + Paclitaxel
Atezolizumab + Paclitaxel
Atezolizumab + Guadecitabine
Atezolizumab + BTCT4465A
Atezolizumab + Entinostat
ALX148 + Atezolizumab
Atezolizumab + DSP-7888
Atezolizumab + FANG vaccine
Atezolizumab + Carboplatin + Nab-paclitaxel
Atezolizumab + Capecitabine + Carboplatin + Gemcitabine
Atezolizumab + Peg-interferon alfa-2a
Atezolizumab + Tocilizumab
Atezolizumab + Cobimetinib + Vemurafenib
Atezolizumab + Cisplatin + Gemcitabine + PEGPH20
Atezolizumab + Ipatasertib + Nab-paclitaxel
Atezolizumab + Eribulin
Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab
Atezolizumab + Bevacizumab + Fulvestrant
Ad-E6E7 + Atezolizumab + MG1-E6E7
Atezolizumab + INO-5401 + INO-9012
Atezolizumab + Idasanutlin
Atezolizumab + Cisplatin + Pemetrexed
Atezolizumab + GDC-0919
Atezolizumab + Obinutuzumab + RO6874281
Atezolizumab + Erlotinib
Atezolizumab + CYT107
Alectinib + Atezolizumab
Atezolizumab + Obinutuzumab
Atezolizumab + Radium Ra 223 dichloride
Atezolizumab + Obinutuzumab + Polatuzumab Vedotin
Atezolizumab + Sipuleucel-T
Atezolizumab + Gemcitabine + Nab-paclitaxel
Atezolizumab + Bevacizumab + Tamoxifen
Atezolizumab + SGN-LIV1A
Atezolizumab + TEN-010
Atezolizumab + Lenalidomide + Obinutuzumab
Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel
Atezolizumab + Enfortumab vedotin + Pembrolizumab
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
Atezolizumab + Isatuximab
Atezolizumab + B-701
Atezolizumab + MV-NIS
Atezolizumab + QbG10
Atezolizumab + PGV 001
Atezolizumab + Bevacizumab + Obinutuzumab + RO6874281
Atezolizumab Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).
Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine + Guadecitabine
Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine
Atezolizumab + FT500
Atezolizumab + Bevacizumab + Peg-interferon alfa-2a
Atezolizumab + Bevacizumab + Entinostat
Atezolizumab + Capecitabine
Atezolizumab + Cyclophosphamide + Doxorubicin
Atezolizumab + PEGPH20
Atezolizumab + Fulvestrant + Ipatasertib
Atezolizumab + Nab-paclitaxel
Atezolizumab + Cisplatin
Atezolizumab + Pegylated liposomal-doxorubicin
Atezolizumab + CPI-444
Atezolizumab + Temozolomide
Atezolizumab + Fluorouracil + Oxaliplatin
Atezolizumab + Rociletinib
Atezolizumab + Sapitinib
Atezolizumab + Bevacizumab + PGG beta-glucan
Atezolizumab + CV301
Anetumab ravtansine + Atezolizumab
Atezolizumab + Bevacizumab + Capecitabine
Atezolizumab + Trastuzumab
Atezolizumab + Carboplatin
Atezolizumab + Interferon alpha-2b
Atezolizumab + TJ004309 Limited information is currently available on TJ004309, a putative CD73 antibody (Feb, 2019).
Atezolizumab + Vemurafenib
Atezolizumab + Daratumumab
Atezolizumab + Cabozantinib
Atezolizumab + RO6874281
Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin
Atezolizumab + Bevacizumab + Pegylated liposomal-doxorubicin
Atezolizumab + BKT140
Atezolizumab + Carboplatin + Etoposide
Atezolizumab + Bevacizumab + Rucaparib Tecentriq (atezolizumab) is a monoclonal antibody that binds to PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with PD-L1-expressing advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy, advanced urothelial carcinoma ineligible for or progressed on platinum-containing therapy regardless of PD-L1 expression, and metastatic non-small cell lung cancer progressed on platinum-containing therapy (FDA.gov).
Atezolizumab + Carboplatin + Etoposide + Trilaciclib
Atezolizumab + MOXR0916
Atezolizumab + Cobimetinib + Eribulin
Atezolizumab + Carboplatin + Paclitaxel
Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin